12.52

2.04% -0.2165

Intellia Therapeutics Inc (NTLA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$12.74

Offen:

$12.5

24-Stunden-Volumen:

1.37M

Relative Volume:

0.30

Marktkapitalisierung:

$1.76B

Einnahmen:

$67.67M

Nettoeinkommen (Verlust:

$-412.69M

KGV:

-3.2727

EPS:

-3.8266

Netto-Cashflow:

$-395.87M

1W Leistung:

-2.19%

1M Leistung:

+4.52%

6M Leistung:

-10.15%

1J Leistung:

+5.05%

1-Tages-Spanne:

$12.23

$12.82

1-Wochen-Bereich:

$12.23

$12.96

52-Wochen-Spanne:

$7.95

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Firmenname

Intellia Therapeutics Inc

Sektor

Healthcare (1087)

Branche

Biotechnology (606)

Telefon

857-285-6200

Adresse

40 ERIE STREET, CAMBRIDGE, MA

Mitarbeiter

377

Twitter

@intelliatweets

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NTLA Intellia Therapeutics Inc	12.54	1.79B	67.67M	-412.69M	-395.87M	-3.8266
VRTX Vertex Pharmaceuticals Inc	522.04	134.06B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	799.73	83.43B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,000.06	63.00B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.54	56.02B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.27	44.44B	742.00K	-1.37B	-1.07B	-7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-02	Hochstufung	William Blair	Mkt Perform → Outperform
2025-11-12	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-11	Herabstufung	Evercore ISI	Outperform → In-line
2025-11-07	Herabstufung	JP Morgan	Neutral → Underweight
2025-10-28	Herabstufung	Bernstein	Outperform → Mkt Perform
2025-10-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-10-27	Herabstufung	Guggenheim	Buy → Neutral
2025-10-27	Herabstufung	William Blair	Outperform → Mkt Perform
2025-10-06	Hochstufung	Citizens JMP	Mkt Perform → Mkt Outperform
2025-04-21	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-03-05	Eingeleitet	H.C. Wainwright	Buy
2025-02-28	Herabstufung	Goldman	Neutral → Sell
2025-02-28	Herabstufung	JP Morgan	Overweight → Neutral
2025-01-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-02-23	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-04-13	Eingeleitet	Canaccord Genuity	Buy
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-03-14	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-24	Hochstufung	Citigroup	Sell → Neutral
2023-01-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2022-10-11	Eingeleitet	Morgan Stanley	Overweight
2022-09-21	Eingeleitet	JP Morgan	Overweight
2022-09-01	Eingeleitet	Citigroup	Sell
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-06-16	Eingeleitet	BofA Securities	Buy
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-02-18	Eingeleitet	William Blair	Outperform
2022-02-07	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-31	Eingeleitet	Cowen	Outperform
2022-01-07	Eingeleitet	Piper Sandler	Overweight
2021-10-05	Eingeleitet	Guggenheim	Buy
2021-09-24	Eingeleitet	Stifel	Buy
2021-06-28	Bestätigt	H.C. Wainwright	Buy
2021-06-11	Eingeleitet	H.C. Wainwright	Buy
2021-05-07	Hochstufung	ROTH Capital	Neutral → Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-03-04	Eingeleitet	JMP Securities	Mkt Outperform
2020-12-22	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-10-27	Eingeleitet	Truist	Buy
2020-10-14	Eingeleitet	Wells Fargo	Overweight
2020-09-18	Eingeleitet	Goldman	Buy
2020-02-28	Hochstufung	Oppenheimer	Perform → Outperform
2020-02-14	Herabstufung	Wedbush	Outperform → Neutral
2019-11-01	Hochstufung	Raymond James	Mkt Perform → Outperform
2019-07-09	Eingeleitet	Robert W. Baird	Outperform
2019-06-10	Eingeleitet	ROTH Capital	Neutral
2019-05-03	Hochstufung	Wedbush	Neutral → Outperform
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2018-11-02	Herabstufung	Wedbush	Outperform → Neutral
2018-10-29	Eingeleitet	Credit Suisse	Neutral
2018-09-21	Eingeleitet	Raymond James	Mkt Perform
2018-05-15	Hochstufung	Chardan Capital Markets	Neutral → Buy
2018-03-08	Eingeleitet	JMP Securities	Mkt Outperform
2017-11-01	Bestätigt	Jefferies	Buy
2017-06-22	Fortgesetzt	Jefferies	Buy
2017-03-28	Eingeleitet	Chardan Capital Markets	Buy
2016-08-05	Hochstufung	Jefferies	Hold → Buy

Alle ansehen

Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten

09:53 AM

NTLA Reiterates by Citizens -- Price Target Maintained at $30 - GuruFocus

09:53 AM

09:37 AM

Intellia Therapeutics Stock Short Interest Rises to 40.35% - Quiver Quantitative

09:37 AM

08:51 AM

NTLA Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus

08:51 AM

H.C. Wainwright reiterates Intellia stock rating on FDA review progress - Investing.com

08:51 AM

08:36 AM

H.C. Wainwright reiterates Intellia stock rating on FDA review progress By Investing.com - Investing.com India

08:36 AM

07:52 AM

NTLA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus

07:52 AM

05:27 AM

Citizens reiterates Intellia stock rating on FDA priority review By Investing.com - Investing.com Canada

05:27 AM

12:20 PM

Citizens reiterates Intellia stock rating on HAE opportunity potential By Investing.com - Investing.com Nigeria

12:20 PM

Sep 08, 2026

Intellia’s Lonvo-z Gains FDA Priority Review for HAE - TipRanks

Sep 08, 2026

Intellia Announces FDA Acceptance of BLA for Lonvo-z with PDUFA Date March 10, 2027 - TradingView

Sep 08, 2026

Intellia Therapeutics Obtains $400M Senior Secured Credit Facility (NASDAQ: NTLA) - Kalkine Media

Sep 08, 2026

Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date - AllSci

Sep 08, 2026

Intellia Therapeutics stock jumps on FDA priority review By Investing.com - Investing.com Nigeria

Sep 08, 2026

Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema - marketscreener.com

Sep 08, 2026

NTLA Looks 4.8% Undervalued on GF Value™ Amid FDA Priority Review - GuruFocus

Sep 08, 2026

Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform - Stocktwits

Sep 08, 2026

Why is Intellia Therapeutics stock rallying today? By Investing.com - Investing.com Canada

Sep 08, 2026

Why is Intellia Therapeutics stock rallying today? - Investing.com

Sep 08, 2026

Intellia stock rises on FDA priority review (NTLA:NASDAQ) - Seeking Alpha

Sep 08, 2026

NTLA Looks 4.0% Undervalued on GF Value™ as FDA Advances Lonvo-z Review - GuruFocus

Sep 08, 2026

Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z - Yahoo Finance

Sep 08, 2026

Intellia Therapeutics stock jumps on FDA priority review - Investing.com

Sep 08, 2026

If approved, a one-time treatment could be the world's first in-body gene-editing therapy for hereditary angioedema. - Stock Titan

Sep 08, 2026

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - Intellia Therapeutics

Sep 08, 2026

FDA grants lonvo-z priority review - CRISPR Medicine News

Sep 08, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 08, 2026

Sep 06, 2026